Veracyte Q2 FY26 swings to GAAP net income of $25.5 million; revenue rises 15% to $150.3 million

• Veracyte posted Q2 2026 GAAP net income of $25.5 million, swinging from a loss; diluted GAAP EPS was $0.31.
• Revenue rose 15% year over year to $150.3 million; testing revenue climbed 19% to $145.7 million.
• Adjusted EBITDA increased 23% to $44 million, lifting adjusted EBITDA margin to 29.2% from 27.5%.
• Total volume grew 13% to 50,967 tests, driven by Decipher testing revenue up 20% to $91.9 million.
• Raised 2026 revenue outlook to $590 million-$596 million; CEO Marc Stapley cited new launches Prosigna LDT, TrueMRD for MIBC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.